Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Clinical trial NCT06479135 · RECRUITING

Trial details

NCT number: NCT06479135
Sponsor: Kartos Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Myelofibrosis Post-PV MF Post-ET Myelofibrosis Primary Myelofibrosis MF

Start date: 2024-06-03
Primary completion: 2026-12-31
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.